This NDC is on FDA's drug shortage list (posted May 3, 2018)
Reported reason: Demand increase for the drug
Product Information
LORAZEPAM 2 MG/ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $2.1715 per ML under NDC 65219036802. Its NADAC has been published 86 times since Feb 12, 2025.
FDA first approved this application on Nov 18, 2024. Its Orange Book therapeutic-equivalence code is AP.
Strength
2 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
65219036802
Classification
Generic
Dosage Form
INJECTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
LORAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA217598FDA Approved
11/18/2024
TE Code
AP
On Market Since
12/13/2024
Pharmacological Classes
Price Statistics
The NADAC for LORAZEPAM 2 MG/ML VIAL has been published 86 times since Feb 12, 2025, and over the history we have for it it has risen 99.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.1715 per ML |
|---|---|
| All-time high | $2.1715 (Sep 30, 2026) |
| All-time low | $1.0891 (Feb 12, 2025) |
| 52-week high | $2.1715 |
| 52-week low | $1.0891 |
| Median price | $1.0891 |
| Average price | $1.3677 |
| Largest weekly change | +54.6% (Mar 18, 2026) |
| Weeks tracked | 86 |
| Tracking since | Feb 12, 2025 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 69% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lorazepam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LORAZEPAM 2 MG/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for LORAZEPAM 2 MG/ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $2.1715 per ML (NDC 65219036802), effective Sep 30, 2026.
How has the price of LORAZEPAM 2 MG/ML VIAL changed over time?
Over the history we have for it, the NADAC for LORAZEPAM 2 MG/ML VIAL has risen 99.4%. It has been tracked across 86 weekly CMS publications since Feb 12, 2025.
What are the highest and lowest recorded NADAC prices for LORAZEPAM 2 MG/ML VIAL?
Since Feb 12, 2025, the NADAC for LORAZEPAM 2 MG/ML VIAL has ranged from a low of $1.0891 (Feb 12, 2025) to a high of $2.1715 (Sep 30, 2026), with a median of $1.0891 per ML.
Are there cheaper alternatives to LORAZEPAM 2 MG/ML VIAL?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LORAZEPAM 20 MG/10 ML VIAL, is $0.6796 per ML — about 69% below LORAZEPAM 2 MG/ML VIAL.
Who manufactures LORAZEPAM 2 MG/ML VIAL?
LORAZEPAM 2 MG/ML VIAL (NDC 65219036802) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.
Is LORAZEPAM 2 MG/ML VIAL in shortage?
Yes — NDC 65219036802 is currently listed in FDA's drug shortage database (posted May 3, 2018). Reported reason: Demand increase for the drug.